Hyperion DeFi (NASDAQ:HYPD) Given New $7.30 Price Target at Chardan Capital

Hyperion DeFi (NASDAQ:HYPD) had its target price decreased by research analysts at Chardan Capital from $8.25 to $7.30 in a report issued on Monday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Chardan Capital’s price target would indicate a potential upside of 144.15% from the stock’s current price.

Several other research analysts have also recently weighed in on HYPD. Cantor Fitzgerald upgraded shares of Hyperion DeFi to a “strong-buy” rating in a research report on Thursday, April 9th. Weiss Ratings restated a “sell (e+)” rating on shares of Hyperion DeFi in a research report on Wednesday, May 20th. Finally, Zacks Research cut shares of Hyperion DeFi from a “hold” rating to a “strong sell” rating in a research report on Monday, March 30th. One analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Hyperion DeFi currently has an average rating of “Hold” and a consensus price target of $5.65.

Hyperion DeFi Stock Performance

HYPD stock opened at $2.99 on Monday. The company has a debt-to-equity ratio of 0.12, a current ratio of 1.97 and a quick ratio of 1.97. The company has a 50 day moving average price of $3.65 and a 200 day moving average price of $3.62. Hyperion DeFi has a fifty-two week low of $2.11 and a fifty-two week high of $17.18. The stock has a market capitalization of $45.32 million, a PE ratio of -0.30 and a beta of 2.47.

Hyperion DeFi (NASDAQ:HYPD) last posted its quarterly earnings data on Thursday, March 26th. The company reported ($7.76) earnings per share for the quarter. The company had revenue of $0.50 million for the quarter. Analysts forecast that Hyperion DeFi will post 1.78 EPS for the current year.

Insider Buying and Selling

In related news, insider Hyunsu Jung acquired 7,000 shares of the business’s stock in a transaction that occurred on Monday, June 1st. The shares were acquired at an average cost of $3.70 per share, with a total value of $25,900.00. Following the transaction, the insider owned 1,384,676 shares of the company’s stock, valued at $5,123,301.20. The trade was a 0.51% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 7.50% of the company’s stock.

Institutional Investors Weigh In On Hyperion DeFi

Several institutional investors have recently added to or reduced their stakes in the stock. Redwood Wealth Management Group LLC lifted its position in Hyperion DeFi by 2.1% in the 1st quarter. Redwood Wealth Management Group LLC now owns 183,273 shares of the company’s stock valued at $632,000 after acquiring an additional 3,690 shares in the last quarter. Price T Rowe Associates Inc. MD bought a new stake in shares of Hyperion DeFi in the 4th quarter valued at about $73,000. State Street Corp bought a new stake in shares of Hyperion DeFi in the 4th quarter valued at about $92,000. Jane Street Group LLC bought a new stake in shares of Hyperion DeFi in the 4th quarter valued at about $493,000. Finally, Renaissance Technologies LLC bought a new stake in shares of Hyperion DeFi in the 4th quarter valued at about $663,000. 25.84% of the stock is owned by institutional investors.

Hyperion DeFi Company Profile

Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.